Nanjing Vazyme Biotech Co., Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Nanjing Novozan Biotechnology Co., Ltd. is a biotechnology enterprise engaged in technological research and product development around functional proteins such as enzymes, antigens, antibodies, and polymer organic materials. Relying on its independently established key common technology platform, it has successively entered the business fields of biotechnology research, in vitro diagnosis, biopharmaceuticals, and so on, It is one of the few R&D and innovative enterprises in China that has both independent and controllable upstream technology development capabilities and terminal product production capabilities. Intelligent manufacturing of "biochips" provides the driving force for the development of the biotechnology industry. Novozan always adheres to innovation, is committed to breakthroughs, and insists on starting research and development from the source of technology. Relying on independent core technology, it builds a key and controllable common technology platform that can quickly, efficiently, and scale up product development. It currently has over 200 genetic engineering recombinant enzymes, over 1000 high-performance antigens and monoclonal antibodies, and other key raw materials. It has over 500 terminal products, which can be widely used in scientific research, high-throughput sequencing, in vitro diagnosis The fields of medicine and vaccine research and development, as well as animal quarantine. Strong R&D capabilities are supported by a talent team. Novozan has a R&D and innovation team of over 400 people, consisting of composite R&D personnel in multiple fields such as molecular biology, enzymology, immunology, bioinformatics, organic chemistry, and materials science. More than 50% of the R&D personnel have a master's degree or above. Since its establishment, Novozan has always adhered to the business philosophy of R&D as the core, relying on independent core technology, continuously updating and upgrading iterative technology, and exploring new business areas. Through years of hard work, Novozan has achieved technological achievements in the field of biomedicine. We have successfully launched multiple series of biological reagents, including high-throughput sequencing library building series, PCR series, qPCR series, molecular cloning series, reverse transcription series, Bio assay series, as well as 8 series of POCT diagnostic reagents, including cardiovascular and cerebrovascular diseases, inflammatory infections, eugenics and eugenics, and gastric function. We have formed a network that covers scientific research institutions, high-throughput sequencing service enterprises, molecular diagnostic reagent production enterprises, pharmaceutical enterprises, CRO enterprises A combination of customers from various customer groups such as hospitals and medical institutions. While expanding and deepening the product and technology chain, Novozem always adheres to the mission of "technology achieves a healthy life", constantly developing new technologies, providing high-quality products and professional services around the "discovery diagnosis prevention treatment" of diseases, and creating value for customers. Novozen is committed to striving for excellence, providing employees with a broad development platform, attracting outstanding talents from all over the country and the world to join, and promoting the overall development and improvement of China's biomedical technology industry. Nuovizan participated in the construction of public health, played an important role in the fight against African swine fever and COVID-19 epidemic, used science and technology to help the national biosafety construction, and helped mankind defeat major infectious diseases, tumors, and autoimmune diseases!. |
| Headquarter | Nanjing |
| Establish Date | 3/16/2012 |
| Listed Code | 688105.SH |
| Listed Date | 11/15/2021 |
| Chairman | Cao Lin. |
| CEO | Cao Lin. |
| Website | www.vazyme.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
